Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
  • All Years
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • All Releases
  • Financial Releases
Jan 04, 2018 7:30am EST

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Dec 15, 2017 7:30am EST

Rigel Announces Departure of Chief Financial Officer

Dec 08, 2017 7:05pm EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Dec 08, 2017 7:30am EST

Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting

Nov 17, 2017 4:05pm EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Nov 07, 2017 4:01pm EST

Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

Nov 02, 2017 7:30am EDT

Rigel Welcomes Gregg Lapointe to Board of Directors

Oct 31, 2017 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results

Oct 10, 2017 4:01pm EDT

Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

Oct 04, 2017 10:36pm EDT

Rigel Announces Pricing Of Public Offering Of Common Stock

  • Previous
  • 1…
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin